Aerosol therapy for children

Respiratory Care Clinics of North America

Volumn 7, Issue 2, 2001, Pages 175-213

  Rubin, Bruce K ^a   Fink, James B ^b  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b AeroGen Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; COLISTIN; CORTICOSTEROID; DNA; GENTAMICIN; LUNG SURFACTANT; SALBUTAMOL; TOBRAMYCIN;

ADULT; AEROSOL; ARTICLE; ASTHMA; BREATHING; CHILD; CHILD CARE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENSITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; GENE TARGETING; GENE THERAPY; HOME CARE; HOSPITAL CARE; HUMAN; HUMIDITY; INFANT; LUNG VENTILATION; NEBULIZATION; NEWBORN; PARTICLE SIZE; RESPIRATORY CARE; TEMPERATURE; VIRUS VECTOR;

EID: 0035173761     PISSN: 10785337     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1078-5337(05)70030-7     Document Type: Article

References (126)

1. Safety of ribavirin with mechanical ventilation
2. The delivery of therapeutic aerosols through endotracheal tubes
3. A comparison of low and high doses of continuously nebulized terbutaline for treatment of severe exacerbations of asthma
4. Clinical Practice Guideline: Selection of aerosol delivery device
5. Deposition in asthmatics of particles inhaled in air or in helium-oxygen
6. Effects of aerosolized surfactant in patient with stable chronic bronchitis: A prospective randomized controlled trial
7. The binding of amikacin to macro-molecules from the sputum of patients suffering from respiratory diseases
8. Continuous in-line nebulizers complicate pressure support ventilation
9. Inspiratory flow rate through the Diskus/Accuhaler inhaler and Turbuhaler inhaler in children with asthma
10. Metered dose inhaler aerosol characteristics are affected by the endotracheal tube actuator/adapter used
11. The diffusion of β-lactam antibiotics through mixed gels of cystic fibrosis-derived mucin and Pseudomonas aeruginosa alginate
12. Fundamentals of the ultrasonic atomization of medicated solutions
13. Deposition of aerosol in the respiratory tract
14. Efficacy of bronchodilators administered by nebulizers versus spacer devices in infants with acute wheezing
15. Continuous nebulization of albuterol (salbutamol) in acute asthma
16. Committee on Infectious Diseases, American Academy of Pediatrics: Ribavirin therapy of respiratory syncytial virus
17. Contaminated medication nebulizers in mechanical ventilator circuits: A source of bacterial aerosols
18. Reduction of morbidity in asthmatic children given a spacer device
19. Use and misuse of metered-dose inhalers by patients with chronic lung disease: A controlled randomized trial of two instruction methods
20. A study of macromolecular diffusion through native porcine mucus
21. Hyporesponsiveness to aerosolized but not to infused methacholine in cigarette-smoking dogs
22. Dose response to bronchodilator delivered by metered-dose inhaler in ventilator-supported patients
23. Albuterol delivery in a model of mechanical ventilation: Comparison of metered-dose inhaler and nebulizer efficiency
24. Evaluation of jet type and ultrasonic nebulizers in mist tent therapy for cystic fibrosis
25. Physical principles underlying aerosol therapy
26. Measurement of the particle size and dosing characteristics of a radiolabelled albuterol-sulphate lactose blend used in the SPIROS dry powder inhaler
27. Pulmonary aerosol deposition in chronic bronchitis: Intermittent positive pressure breathing vs quiet breathing
28. A comparative study of two doses of salbutomol nebulized at 4 and 8 L/min in patients with chronic asthma
29. Short term efficacy of ultrasonically nebulized hypertonic saline incystic fibrosis
30. Peak inspiratory flowrate and inspiratory vital capacity of patients with asthma measured with and without a new dry powder inhaler device (Turbuhaler)
31. Heliox increased delivery of albuterol from a MDI during mechanical ventilation: An in vitro model
32. Aerosol therapy
33. Bronchodilator therapy in mechanically ventilated patients
34. Deposition of aerosol from metered-dose inhaler during mechanical ventilation: An in vitro model
35. Reconciling in vitro and in vivo measurements of aerosol delivery from a metered-dose inhaler during mechanical ventilation and defining efficiency-enhancing factors
36. In vivo gene therapy with adeno-associated virus vectors for cystic fibrosis
37. Efficiency of bronchodilator aerosol delivery to the lungs from the metered dose inhaler in mechanically ventilated patients: A study comparing four different actuator devices
38. The generation of respirable clouds from coarse powder aggregates
39. Uber inhalation von insulin
40. Albuterol delivery by metered-dose inhaler with a pediatric mechanical ventilatory circuit model
41. Improvements in aerosol delivery with helium-oxygen mixtures during mechanical ventilation
42. Bronchodilator therapy
43. Incorrect use of metered dose inhalers by medical personnel
44. Is driving gas flow clinically important for nebulizer therapy?
45. An outbreak of Burkholderia (formerly Pseudomonas) cepacia respiratory tract colonization and infection associated with nebulized albuterol therapy
46. Reduction in patient timing errors using a breath-activated metered dose inhaler
47. Reproductive risk assessment with occupational exposure to ribavirin aerosol
48. Effect of a spacer on pulmonary aerosol deposition from a jet nebulizer during mechanical ventilation
49. Time-action profile of inhaled insulin
50. Medication nebulizer performance: Effects of diluent volume, nebulizer flow, and nebulizer brand
51. The effect of heliox on nebulizer function using a β-agonist bronchodilator
52. A comparison of the performance of two modern multidose dry powder asthma inhalers
53. Dose emissions from marketed dry powder inhalers
54. Effects of nebulizer mode and position in a mechanical ventilator circuit on dose efficiency
55. Crying significantly reduces absorption of aerosolized drug in infants
56. Plasma levels and effects of salbutamol after inhaled or IV administration in stable asthma
57. Intrapulmonary administration of insulin to healthy volunteers
58. Delivery of albuterol and ipratropium bromide from two nebulizer systems in chronic stable asthma: Efficacy and pulmonary deposition
59. Evaluation of a double-enclosure double-vacuum unit scavenging system for ribavirin administration
60. Patient handling of a multidose dry powder inhalation device for albuterol
61. Pulmonary surfactant as a vehicle for intratracheal delivery of technetium sulfur colloid and pentamidine in hamster lungs
62. Alteration of airway reactivity by mucus
63. A controlled study of adenovirus-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis
64. The effect of adding ipratropium to salbutamol in the treatment of acute asthma: A pooled analysis of three trials
65. Evaluation of conventional press-and-breathe metered-dose inhaler technique in 501 patients
66. The lung as an alternative route for delivery for insulin in controlling postprandial glucose levels in patients with diabetes
67. Ultrasonic and jet nebulizers: Differences in the physical properties and fractional deposition on the airway responses to nebulized water and saline aerosols
68. Superiority of ipratropium plus albuterol over albuterol alone in the emergency department management of adults asthma: A randomized clinical trial
69. Metered dose inhaler and nebulizer in acute asthma
70. Facemasks versus mouthpieces for aerosol treatment of asthmatic children
71. Inhalation route for administration of systemic drugs
72. Optimal duration of nebulized albuterol therapy
73. Metered-dose inhaler versus nebulized albuterol in mechanically ventilated patients
74. Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease
75. Fraction of dose exhaled after administration of pressurized inhalation aerosols
76. Ultrasonic nebulization of albuterol is no more effective than jet nebulization for the treatment of acute asthma in children
77. Aerosol Therapy in Children: Basic Mechanisms of Pediatric Respiratory Disease: Cellular and Integrative
78. Control of asthma by aerosols
79. Rapid temperature change from +25°C to -15°C impairs powder deaggregation in Bricanyl Turbuhaler
80. Simple instructions for using pressurized aerosol bronchodilators
81. Nebulizer performance, pharmokinetics, airways and systemic effects of salbutamol given via a novel nebulizer system (Ventstream)
82. Bacterial contamination of aerosol solutions containing antibiotics
83. Nebulizer function during mechanical ventilation
84. Aerosol deposition in mechanically ventilated patients: Optimizing nebulizer delivery
85. Delivery options for the inhaled therapy in children over the age of 6 years
86. Delivery systems in children
87. Influence of inspiratory flowrate upon the effect of a Turbuhaler
88. The therapeutic use of ultrasonic nebulizers in acute asthma
89. Continuous terbutaline nebulization for the treatment of severe exacerbations of asthma in children
90. Effect of nebulized ipratropium on the hospitalization rates of children with asthma
91. Testing of dry powder aerosol formulations in different environmental conditions
92. Efficacy of aerosolized tobramcin in patients with cystic fibrosis
93. Evaluation of a reservoir device for metered-dose bronchodilator delivery to intubated adults: An in vitro study
94. Nebulized anticholinergic and sympathomimetic treatment of asthma and chronic obstructive airway in the disease in the emergency room
95. Emerging therapies for cystic fibrosis lung disease
96. Pressurized metered-dose inhalers and holding chambers for inhaled glucocorticoid therapy in childhood asthma
97. Tracheomalacia as a cause of respiratory compromise in infants
98. Use of anticholinergic bronchodilation in children
99. Oropharyngeal Candidiasis in patients treated with beclomethasone dipropionate delivered by metered-dose inhaler alone and with Aerochamber
100. Efficacy of frequent nebuilized ipratropium bromide added to frequent high-dose albuterol therapy in severe childhood asthma
101. High-versus low-dose, frequently administered nebulized albuterol in children with severe acute asthma
102. Surfactant displaces particles toward the epithelium in airways and alveoli
103. Influence of flow rate on particle size distributions from pressurised and breath actuated inhalers
104. Effects of repetitive use and cleaning techniques of disposable jet nebulizers on aerosol generation
105. The effect of mucolytic agents on gene transfer across a CF sputum barrier in vitro
106. Aerosol bronchodilator delivery methods' relative impact on pulmonary function and cost of respiratory care
107. Added external resistance reduces oropharyngeal deposition and increases lung deposition of aerosol particles in asthmatics
108. Human lung deposition of particles suspended in air or in helium/oxygen mixture
109. Effect of bromhexeine on sputum amoxycillin levels in lower respiratory infections
110. Improving the efficiency of drug administration with jet nebulisers
111. Delivery of ultrasonic nebulized aerosols to a lung model during mechanical ventilation
112. Pulmonary deposition of a nebulized aerosol during mechanical ventilation
113. Lung deposition from Turbuhaler is twice that from a pressurized metered-dose inhaler (pMDI)
114. The effect of inhalation flow on the performance of a dry powder inhalation system
115. Use of spacer to facilitate inhaled corticosteroid treatment of asthma
116. Delivery of albuterol in a pediatric emergency department
117. Aerosolized recombinant human DNase in hospitalised cystic fibrosis patients with acute pulmonary exacerbations
118. Effect of random airway sizes on aerosol deposition
119. Comparison of the effects on lung function of two methods of bronchodilator administration
120. Ipratropium added to asthma treatment in the pediatric emergency department